search
Back to results

Port Wine Stains Treatment Matrix RF Study

Primary Purpose

Port Wine Stains

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Matrix RF
Matrix RF followed by Pulse Dye Laser
Pulse Dye Laser followed by Matrix RF
Sponsored by
Syneron Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Port Wine Stains focused on measuring port wine stains, radiofrequency, Pulse Dye Laser

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Informed consent agreement signed by the subject.
  • Healthy males or females older than 18 to 65 years of age.
  • Having a low to mid depth Port Wine Stain of at least 5 cm2.
  • Willingness to follow the treatment and follow-up schedule and the post-treatment care.
  • For female candidates - post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide, or abstinence).

Exclusion Criteria:

  • PWS on lower legs or hands.
  • Pregnant and/or breastfeeding.
  • Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
  • Having a permanent implant in the treated area, such as an injected chemical substance in the face (if treated).
  • Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treated area, unless treatment is conducted following a prophylactic regimen.
  • Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) one week before and after each treatment session.
  • Use of retinoids, antioxidants or medical grade of skin nourishing supplements within 2 months of treatment or during the study.
  • Having received a facial dermabrasion or chemical peel treatment within 3 months of treatment or during the study (if face is treated).
  • Having received treatment with light, RF or other devices in the treated area within 6 months of treatment or during the study.
  • Having received Botox/collagen/fat injections or other methods of augmentation with injected or implanted material in the treated area within 9 months of treatment or during the study (if face is treated).
  • Having undergone a resurfacing procedure, face lift or eyelid surgery within a year of treatment or during the study (if face is treated).
  • Having undergone any other surgery in the treated area within 6 months of treatment (or more if skin has not healed completely) or during the study.
  • History of keloid scarring or of abnormal wound healing.
  • Suffering from current or history of significant skin conditions in the treated area or inflammatory skin conditions, including, but not limited to: active acne, excessive skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage), varicella scars, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
  • History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
  • History of epidermal or dermal disorders (particularly if involving collagen or microvascularity).
  • History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
  • Suffering from hormonal imbalance, as per the Investigator's discretion.
  • Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
  • Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including actinic keratosis, presence of malignant or pre-malignant pigmented lesions.
  • Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), or pertinent neurological disorders.
  • Tattoo or permanent make-up in the treated area.
  • Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
  • Participation in a study of another device or drug within three month prior to enrollment or during the study.
  • As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Sites / Locations

  • Laser and Skin Surgery Center of New York

Arms of the Study

Arm 1

Arm Type

Active Comparator

Arm Label

Matrix RF followed by Pulse Dye Laser

Arm Description

Outcomes

Primary Outcome Measures

Time to complete healing
Assess safety of the Matrix RF treatment for port wine stains
Adverse events recording and monitoring

Secondary Outcome Measures

Clearance of port wine stain
Lightening of the port wine stain
Evaluation of lightening of the port wine stain will be made with reflectance spectrophotometer at all treatments and at 6 and 12 weeks following the last treatment.
Improvement of port wine stain
Assessment to be done by the subject via subject questionnaire during these visits
Reduction in blood vessel concentration
Biopsies taken from consenting subjects at one of the time points will be analyzed

Full Information

First Posted
April 7, 2010
Last Updated
November 30, 2014
Sponsor
Syneron Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT01101360
Brief Title
Port Wine Stains Treatment Matrix RF Study
Official Title
Evaluation of Fractional Radiofrequency (Matrix RF) Stand Alone and Combined With PDL Treatment on Port Wine Stains
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
September 2011 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Syneron Medical

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy and safety of the Matrix RF for Port Wine Stains based on clinical and histological analyses.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Port Wine Stains
Keywords
port wine stains, radiofrequency, Pulse Dye Laser

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Matrix RF followed by Pulse Dye Laser
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Matrix RF
Intervention Description
Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
Intervention Type
Device
Intervention Name(s)
Matrix RF followed by Pulse Dye Laser
Intervention Description
Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
Intervention Type
Device
Intervention Name(s)
Pulse Dye Laser followed by Matrix RF
Intervention Description
Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
Primary Outcome Measure Information:
Title
Time to complete healing
Description
Assess safety of the Matrix RF treatment for port wine stains
Time Frame
Up to 30 weeks
Title
Adverse events recording and monitoring
Time Frame
Up to 40 weeks
Secondary Outcome Measure Information:
Title
Clearance of port wine stain
Time Frame
Up to 40 weeks
Title
Lightening of the port wine stain
Description
Evaluation of lightening of the port wine stain will be made with reflectance spectrophotometer at all treatments and at 6 and 12 weeks following the last treatment.
Time Frame
Up to 40 weeks
Title
Improvement of port wine stain
Description
Assessment to be done by the subject via subject questionnaire during these visits
Time Frame
Up to 30 weeks
Title
Reduction in blood vessel concentration
Description
Biopsies taken from consenting subjects at one of the time points will be analyzed
Time Frame
Up to 40 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Informed consent agreement signed by the subject. Healthy males or females older than 18 to 65 years of age. Having a low to mid depth Port Wine Stain of at least 5 cm2. Willingness to follow the treatment and follow-up schedule and the post-treatment care. For female candidates - post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide, or abstinence). Exclusion Criteria: PWS on lower legs or hands. Pregnant and/or breastfeeding. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator. Having a permanent implant in the treated area, such as an injected chemical substance in the face (if treated). Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treated area, unless treatment is conducted following a prophylactic regimen. Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) one week before and after each treatment session. Use of retinoids, antioxidants or medical grade of skin nourishing supplements within 2 months of treatment or during the study. Having received a facial dermabrasion or chemical peel treatment within 3 months of treatment or during the study (if face is treated). Having received treatment with light, RF or other devices in the treated area within 6 months of treatment or during the study. Having received Botox/collagen/fat injections or other methods of augmentation with injected or implanted material in the treated area within 9 months of treatment or during the study (if face is treated). Having undergone a resurfacing procedure, face lift or eyelid surgery within a year of treatment or during the study (if face is treated). Having undergone any other surgery in the treated area within 6 months of treatment (or more if skin has not healed completely) or during the study. History of keloid scarring or of abnormal wound healing. Suffering from current or history of significant skin conditions in the treated area or inflammatory skin conditions, including, but not limited to: active acne, excessive skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage), varicella scars, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity). History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation. Suffering from hormonal imbalance, as per the Investigator's discretion. Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion). Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including actinic keratosis, presence of malignant or pre-malignant pigmented lesions. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), or pertinent neurological disorders. Tattoo or permanent make-up in the treated area. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study. Participation in a study of another device or drug within three month prior to enrollment or during the study. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Facility Information:
Facility Name
Laser and Skin Surgery Center of New York
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Port Wine Stains Treatment Matrix RF Study

We'll reach out to this number within 24 hrs